Show simple item record

dc.rights.licenseAtribución-NoComercial 4.0 Internacional
dc.contributor.advisorCortés Luna, Jorge Alberto
dc.contributor.advisorAlvarez Moreno, Carlos Arturo
dc.contributor.authorOrtiz Roa, Cynthia
dc.date.accessioned2023-02-07T15:56:56Z
dc.date.available2023-02-07T15:56:56Z
dc.date.issued2023
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/83351
dc.descriptionilustraciones, tablas
dc.description.abstractObjetivos Determinar la mortalidad por Candida auris en comparación con otras especies de Candida spp. en pacientes adultos con candidemia. Métodos Se realizó una cohorte retrospectiva de adultos con candidemia en 7 instituciones de Colombia entre 2016 y 2021. El desenlace primario fue la mortalidad a 30 días y el secundario la estancia hospitalaria entre los supervivientes. Se realizó el ajuste de las variables de confusión utilizando pesos de la probabilidad inversa del puntaje de propensión de la exposición (candidemia por C. auris), modelos de supervivencia (Weibull) y de conteo binomial negativo. Resultados De 512 pacientes con candidemia, 244 (47.6%) fallecieron en los primeros 30 días. La mortalidad cruda en C. auris fue 38.1% vs. 51.1% en las otras especies (CNA). En el modelo de Weibull, la mortalidad en el grupo con C. auris fue menor (HR ajustado – aHR0.69, IC 95%: 0.53 -0.90). El tratamiento antimicótico también tuvo un efecto en disminución de la mortalidad, aHR 0.36 (IC 95%: 0.27 -0.47), mientras que la presencia de choque séptico en la evolución del paciente la aumentó, aHR: 1.73 (IC 95% 1.41 – 2.13). En los pacientes que sobrevivieron, no se identificó un efecto de C. auris sobre la estancia hospitalaria, con una razón de tasas de incidencia de 0.92 (IC95%: 0.68-1.22). Conclusiones La mortalidad en pacientes con candidemia por C. auris parece ser menor, al ajustar por numerosas variables confundidoras, el tratamiento y la presencia de choque en la evolución del paciente. No se identificó un efecto significativo de C. auris sobre la estancia hospitalaria en los pacientes que sobrevivieron. (Texto tomado de la fuente)
dc.description.abstractObjective To determine the mortality due to Candida auris in comparison with other species of Candida spp. in adult patients with candidemia. Methods A retrospective cohort of adults with candidemia was conducted at 7 institutions in Colombia between 2016 and 2021. The primary outcome was 30-day mortality, and the secondary was the survivor’s hospital stay. Adjustment for confounding variables was performed using inverse probability weights of exposure propensity score (C. auris candidemia), survival (Weibull) and negative binomial count models. Results Of 512 patients with candidemia, 244 (47.6%) died in the first 30 days. Crude mortality in C. auris was 38.1% vs. 51.1% in other species (CNA). In the Weibull model, mortality in the C. auris group was lower (adjusted HR – aHR- 0.69, 95% CI: 0.53 -0.90). Antifungal treatment also had an effect in reducing mortality, aHR 0.36 (95% CI: 0.27 -0.47), while the presence of septic shock in the patient's evolution increased it, aHR: 1.73 (95% CI 1.41 – 2.13). In surviving patients, no effect of C. auris on hospital stay was identified, with an incidence rate ratio of 0.92 (95% CI: 0.68-1.22). Conclusions Mortality in patients with candidemia due to C. auris appears to be lower, when adjusting for numerous confounding variables, treatment, and the presence of shock in the patient's evolution. No significant effect of C. auris on hospital stay was identified in surviving patients.
dc.format.extentxvi, 32 páginas
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.publisherUniversidad Nacional de Colombia
dc.rightsDerechos reservados al autor, 2023
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.ddc610 - Medicina y salud::616 - Enfermedades
dc.title¿Es la mortalidad atribuible a Candida auris mayor que la mortalidad atribuible a otras especies de Candida spp. en pacientes con candidemia en Colombia?
dc.typeTrabajo de grado - Especialidad Médica
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.publisher.programBogotá - Medicina - Especialidad en Infectología
dc.coverage.countryColombia
dc.description.degreelevelEspecialidades Médicas
dc.description.degreenameEspecialista en Infectología
dc.identifier.instnameUniversidad Nacional de Colombia
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourlhttps://repositorio.unal.edu.co/
dc.publisher.facultyFacultad de Medicina
dc.publisher.placeBogotá, Colombia
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.relation.referencesPappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE; NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003 Sep 1;37(5):634-43.
dc.relation.referencesSatoh K, Makimura K, Hasumi Y, et al. Candida auris sp. Nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 2009; 53:41–44.
dc.relation.referencesForsberg K, Woodworth K, Walters M, Berkow EL, Jackson B, Chiller T, Vallabhaneni S. Candida auris: The recent emergence of a multidrug-resistant fungal pathogen. Med Mycol. 2019 Jan 1;57(1):1-12. Doi: 10.1093/mmy/myy054.
dc.relation.referencesChatterjee S, Alampalli SV, Nageshan RK, Chettiar ST,Joshi S,Tatu US. Draftgenome of a commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genomics 2015; 16:686
dc.relation.referencesForsberg K, Woodworth K, Walters M, Berkow EL, Jackson B, Chiller T, Vallabhaneni S. Candida auris: The recent emergence of a multidrug-resistant fungal pathogen. Med Mycol. 2019 Jan 1;57(1):1-12. Doi: 10.1093/mmy/myy054.
dc.relation.referencesLockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses [published correction appears in Clin Infect Dis. 2018 Aug 31;67(6):987]. Clin Infect Dis. 2017;64(2):134-140.
dc.relation.referencesCDC. Antibiotic Resistant Threats in The United States 2019. Disponible en: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Visitado: 02 de enero de 2023
dc.relation.referencesWHO fungal priority pathogens list to guide research, development and public health action. ISBN 978-92-4-006024-1 Disponible en: https://www.who.int/publications/i/item/9789240060241
dc.relation.referencesWelsh RM, Bentz ML, Shams A et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic healthcare surface. J Clin Microbiol. 2017; 55: 2996–3005).
dc.relation.referencesLone SA, Ahmad A. Candida auris-the growing menace to global health. Mycoses. 2019 Aug;62(8):620-637.
dc.relation.referencesChen J, Tian S, Han X, Chu Y, Wang Q, Zhou B, Shang H. Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris. BMC Infect Dis. 2020 Nov 11;20(1):827.
dc.relation.referencesSarma S, Upadhyay S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resist. 2017;10:155‐165.
dc.relation.referencesCarvajal-Valencia, Silvia K., Lizarazo, Diana, Duarte, Carolina, & Escandon, Patricia. (2020). Identificación de aislamientos de Candida auris recuperados a través de la vigilancia por laboratorio en Colombia: un reto para el diagnóstico. Infectio, 24(4), 224-228. https://doi.org/10.22354/in.v24i4.880
dc.relation.referencesAlgorithm to identify Candida auris based on phenotypic laboratory method and initial species identification. National Center for Emerging and Zoonotic Infectious Diseases. Centers for Disease Control and Prevention CDC. Last updated 9/11/19. Disponible en: https://www.cdc.gov/fungal/candida-auris/pdf/Testing-algorithm_by-Method_508.pdf
dc.relation.referencesSayeed MA, Farooqi J, Jabeen K, Mahmood SF. Comparison of risk factors and outcomes of Candida auris candidemia with non-Candida auris candidemia: A retrospective study from Pakistan. Med Mycol. 2020 Aug 1;58(6):721-729. doi: 10.1093/mmy/myz112
dc.relation.referencesMoin S, Farooqi J, Rattani S, Nasir N, Zaka S, Jabeen K. C. auris and non-C. auris candidemia in hospitalized adult and pediatric COVID-19 patients; single center data from Pakistan. Med Mycol. 2021 Dec 3;59(12):1238-1242. doi: 10.1093/mmy/myab057
dc.relation.referencesSimon SP, Li R, Silver M, Andrade J, Tharian B, Fu L, Villanueva D, Abascal DG, Mayer A, Truong J, Figueroa N, Ghitan M, Chapnick E, Lin YS. Comparative Outcomes of Candida auris Bloodstream Infections: A Multicenter Retrospective Case-control Study. Clin Infect Dis. 2022 Sep 5:ciac735. doi: 10.1093/cid/ciac735.
dc.relation.referencesWatkins RR, Gowen R, Lionakis MS, Ghannoum M. Update on the Pathogenesis, Virulence, and Treatment of Candida auris. Pathog Immun. 2022 Oct 21;7(2):46-65. doi: 10.20411/pai.v7i2.535
dc.relation.referencesDu H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 2020 Oct 22;16(10):e1008921. doi: 10.1371/journal.ppat.1008921.
dc.relation.referencesYue H, Bing J, Zheng Q, Zhang Y, Hu T, Du H, et al. Filamentation in Candida auris, an emerging fungal pathogen of humans: passage through the mammalian body induces a heritable phenotypic switch. Emerg Microbes Infect. 2018; 7(1):188. Epub 2018 Nov 30. https://doi.org/10.1038/s41426-018-0187-x PMID: 30482894.
dc.relation.referencesCortés JA, Ruiz JF, Melgarejo-Moreno LN, Lemos EV. Candidemia en Colombia. Biomédica. 2020;40:195-207.
dc.relation.referencesAlba Ruiz-Gaitán, Héctor Martínez, Ana María Moret, Eva Calabuig, María Tasias, Ana Alastruey-Izquierdo, Óscar Zaragoza, Joan Mollar, Juan Frasquet, Miguel Salavert- Lletí, Paula Ramírez, José Luis López-Hontangas & Javier Pemán (2019): Detection and treatment of Candida auris in an outbreak situation: risk factors for developing colonization and candidemia by this new species in critically ill patients, Expert Review of Anti-infective Therapy, DOI: 10.1080/14787210.2019.1592675
dc.relation.referencesSchelenz, S., Hagen, F., Rhodes, J.L. et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control 5, 35 (2016).
dc.relation.referencesKenters N, Kiernan M, Chowdhary A, Denning DW, Pemán J, Saris K, et al. Control of Candida auris in healthcare institutions: Outcome of an International Society for Antimicrobial Chemotherapy expert meeting. Int J Antimicrob Agents. 2019; 54:400-6.
dc.relation.referencesSayeed MA, Farooqi J, Jabeen K, Awan S, Mahmood SF. Clinical spectrum and factors impacting outcome of Candida auris: a single center study from Pakistan. BMC Infect Dis. 2019 May 6;19(1):384.
dc.relation.referencesMizusawa M, Miller H, Green R, Lee R, Durante M, Perkins R, Hewitt C, Simner PJ, Carroll KC, Hayden RT, Zhang SX. Can Multidrug-Resistant Candida auris Be Reliably Identified in Clinical Microbiology Laboratories? J Clin Microbiol. 2017 Feb;55(2):638-640. doi: 10.1128/JCM.02202-16
dc.relation.referencesKathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, et al. Mul- tidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method. J Clin Mi- crobiol 2015;53:1823–30.
dc.relation.referencesLamoth F, Lewis RE, Kontoyiannis DP. Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections. J Fungi (Basel). 2020 Dec 30;7(1):17. doi: 10.3390/jof7010017.
dc.relation.referencesPappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933
dc.relation.referencesCornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37. doi: 10.1111/1469-0691.1203
dc.relation.referencesAslam S, Rotstein C; AST Infectious Disease Community of Practice. Candida infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13623. doi: 10.1111/ctr.13623
dc.relation.referencesKollef M, Micek S,Hampton N,Doherty JA, Kumar A.Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 2012; 54:1739–46.
dc.relation.referencesAndes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110–22
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.subject.decsMicosis
dc.subject.decsMycoses
dc.subject.decsUnidades de Cuidados Intensivos
dc.subject.decsIntensive Care Units
dc.subject.proposalCandida auris
dc.subject.proposalCandidemia
dc.subject.proposalAntimicóticos
dc.subject.proposalCuidado Intensivo
dc.subject.proposalAntifungals
dc.subject.proposalIntensive Care
dc.subject.proposalColombia
dc.title.translatedIs the mortality attributable to Candida auris greater than the mortality attributable to other Candida spp. in patients with candidemia in Colombia?
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2
dcterms.audience.professionaldevelopmentEstudiantes
dcterms.audience.professionaldevelopmentInvestigadores


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 4.0 InternacionalThis work is licensed under a Creative Commons Reconocimiento-NoComercial 4.0.This document has been deposited by the author (s) under the following certificate of deposit